Financière de Tubize S.A.
TUB
Kedudukan dalam Saham
#2038
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
Harga Saham
$222.81
Modal Pasaran
$9.92B
Perubahan (1 hari)
9.98%
Perubahan (1 tahun)
-15.48%
Negara
BE
Perdagangan Financière de Tubize S.A. (TUB)
Kategori
Healthcare
Hasil untuk Financière de Tubize S.A. (TUB)
Hasil pada Jun 2026 TTM: 0.00
Menurut laporan kewangan terkini daripada Financière de Tubize S.A., hasil semasa syarikat (TTM) ialah 0.00. Pada tahun 2024, syarikat memperoleh hasil sebanyak $13.79K peningkatan berbanding hasil pada tahun 2023 iaitu 0.00. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Financière de Tubize S.A. dari 2003 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | $13.79K | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $8.74K | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | -100.00% |
| 2019 | $4.49K | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | -100.00% |
| 2016 | $317.76K | 29,164.42% |
| 2015 | $1.09K | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | -100.00% |
| 2004 | $2.71K | 0.00% |
| 2003 | 0.00 | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
